Skin Manifestations Associated with Chemotherapy in Children with Hematologic Malignancies

Abstract:  Chemotherapy used in the treatment of malignancies produces multiple mucocutaneous adverse reactions that may be clinically challenging. These mucocutaneous reactions are common and sometimes not diagnosed. The objective of this study was to determine the clinical patterns of the mucocutaneous manifestations during and after chemotherapy in children with a hematologic malignancy and to determine whether nutritional status influences the clinical presentation. We recruited patients aged 6 months to 16 years diagnosed with leukemia and lymphoma from a pediatric hematology outpatient clinic between November 2008 and May 2010. The patients were divided into two groups: Group 1, recently diagnosed patients, included in the study before receiving chemotherapy, and Group 2, patients in surveillance who had not had chemotherapy for at least 3 months. A dermatologic examination was performed, and biopsy and mycological and bacteriological tests were conducted if necessary, with 6 months of follow‐up. We evaluated 89 patients and included 65 in the study: 40 boys and 25 girls with an average age of 8.3 years. All patients had skin lesions at some time during their baseline assessment or follow‐up. The manifestations found were anagen effluvium, xerosis, and acral hyperpigmentation. To our knowledge, this is the first comparative study of skin manifestations associated with chemotherapy in a Mexican pediatric population. The mucocutaneous manifestations associated with chemotherapy are important causes of morbidity. All of the children in our study had skin lesions on assessment. We did not find an association between skin manifestations and nutritional status.

[1]  A. Tosti,et al.  Drug reactions affecting hair: diagnosis. , 2007, Dermatologic clinics.

[2]  S. Chaffee,et al.  Methotrexate-induced bullous acral erythema in a child. , 2005, Journal of the American Academy of Dermatology.

[3]  B. Guillot,et al.  Mucocutaneous side effects of antineoplastic chemotherapy , 2004, Expert Opinion on Drug Safety.

[4]  D. Jukic,et al.  Inflammation of seborrheic keratoses caused by cytarabine: a pseudo sign of Leser-Trelat. , 2004, Journal of drugs in dermatology : JDD.

[5]  C. Kennedy,et al.  Cutaneous Recall Reactions with Systemic Fluorouracil , 2003, Dermatology.

[6]  David Khayat,et al.  Changing patient perceptions of the side effects of cancer chemotherapy , 2002, Cancer.

[7]  L. Schuchter,et al.  Cutaneous toxicities of cancer therapy , 2002, Current opinion in oncology.

[8]  C. H. Yang,et al.  Inflammation of seborrheic keratoses due to docetaxel treatment. , 2001, Acta dermato-venereologica.

[9]  S. Hussain,et al.  Onycholysis as a complication of systemic chemotherapy , 2000 .

[10]  J. Grant-Kels,et al.  Mucocutaneous reactions to chemotherapy. , 1999, Journal of the American Academy of Dermatology.

[11]  M. Raderer,et al.  Anal pruritus after cancer chemotherapy with gemcitabine. , 1999, The New England journal of medicine.

[12]  M. Bayık,et al.  Chemotherapy‐induced acral erythema in leukemic patients: a report of 15 cases , 1997, International journal of dermatology.

[13]  Q. S. Ringenberg,et al.  Vascular toxicity associated with antineoplastic agents. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Sanborn,et al.  Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. , 2008, Dermatologic clinics.

[15]  K. Holland,et al.  Intertriginous eruption associated with chemotherapy in pediatric patients. , 2007, Archives of dermatology.

[16]  D. Sachs,et al.  Cutaneous Reactions to Chemotherapy and their Management , 2006, American journal of clinical dermatology.

[17]  S. Hussain,et al.  Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. , 2000, Cancer.